Figure 4.
Schematic diagram summarizing significant relationships between bevacizumab exposure, the AE trajectory group, clinical outcomes, and patient-reported outcomes. The thickest arrow indicates P < .001, medium arrows indicate P < .01, and thin arrows indicate P < .05. For Cardiac Traj group → physical well-being domain, P = .054. AE indicates adverse event; Cardiac, Cardiac Traj group; Neuro, Neuro Traj group; Mixed Reactions, Mixed Reactions Traj group, Low AE, Low AE Traj group.